Drug Trial Radar · NCT03586570
A Study to Evaluate How Aprocitentan is Safe and How it is Absorbed and Broken Down in the Body of Japanese and Caucasian Subjects
Last checked: Nov 19, 2026Latest source record: Nov 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Jul 17, 2018
Primary completion
Sep 10, 2018
Study completion Sep 10, 2018
Sponsor
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Janssen Biotech, Inc.
- First posted
- Jul 13, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the tolerability, safety, and pharmacokinetics after multiple-dose administration of aprocitentan (25 mg) in healthy Japanese and Caucasian subjects.
Conditions
- Healthy Subjects
Interventions
Aprocitentan 25mgDrug
Oral tablets in strength of 25 mg
PlaceboDrug
Oral tablets matching aprocitentan tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax during the first and last dosing intervalTime frame: From study treatment administration to 216 hours after last administration
- Time to reach Cmax (tmax) during the first and last dosing intervalTime frame: From study treatment administration to 216 hours after last administration
- AUCτ on the first and last day of study treatment intakeTime frame: From study treatment administration to 216 hours after last administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Anaheim Clinical Trials
Anaheim, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.